|Bid||74.63 x 500|
|Ask||74.74 x 600|
|Day's Range||73.19 - 74.42|
|52 Week Range||63.76 - 84.15|
|PE Ratio (TTM)||7.86|
|Dividend & Yield||2.08 (2.82%)|
|1y Target Est||N/A|
Gilead Sciences (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.
PepsiCo, Gilead Sciences, and Colgate-Palmolive can protect income portfolios during a market crash.
Glaxo shares dipped near a two-week low after Gilead's HIV drug combination proved to be non-inferior in a late-stage trial.